Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-ESCALaTE: Cetuximab vs Cisplatin in HPV+ OPSCC
NCT01874171Phase 3Unknown
- Sponsor
- University of Warwick
- Start
- Nov 2012
- Primary completion
- Feb 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of cetuximab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by University of Warwick. Status: unknown.
02
Drugs
cetuximab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT01874171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01874171.